Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MoonLake Immunotherapeutics (MLTX : NSDQ)

• Company Description    MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company. It focused on creating next-level therapies for inflammatory skin and joint diseases. MoonLake Immunotherapeutics AG, formerly known as Helix Acquisition Corp., is based in BOSTON. Number of Employees: 130

• Price / Volume Information    Yesterday's Closing Price: $14.94 Daily Weekly Monthly 20 Day Moving Average: 1,139,550 shares Shares Outstanding: 85.11 (millions) Market Capitalization: $1,271.49 (millions) Beta: 1.04 52 Week High: $62.75 52 Week Low: $5.95 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.95% -9.30% 12 Week -21.29% -22.95% Year To Date 13.35% 1.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL DORFSTRASSE 29 - ZUG,V8 6300 CHE ph: 41-41-510-8022 fax: - ir@moonlaketx.com http://www.moonlaketx.com

• General Corporate Information    Officers Jorge Santos da Silva - Chief Executive Officer; Director Simon Sturge - Chairperson; Director Matthias Bodenstedt - Chief Financial Officer Spike Loy - Director Catherine Moukheibir - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 61559X104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/04/26 Share - Related Items Shares Outstanding: 85.11 Most Recent Split Date: (:1) Beta: 1.04 Market Capitalization: $1,271.49 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.77 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.34 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.92 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 3.45% vs. Previous Quarter: 14.29% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -82.53 03/31/26 - -85.15 12/31/25 - -66.56 ROA 06/30/26 - -58.17 03/31/26 - -60.52 12/31/25 - -50.23 Current Ratio 06/30/26 - 12.56 03/31/26 - 8.60 12/31/25 - 9.27 Quick Ratio 06/30/26 - 12.56 03/31/26 - 8.60 12/31/25 - 9.27 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 5.12 03/31/26 - 3.52 12/31/25 - 4.27 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.23 03/31/26 - 0.39 12/31/25 - 0.24 Debt-to-Capital 06/30/26 - 18.86 03/31/26 - 28.05 12/31/25 - 19.57

Powered by Zacks Investment Research ©